ECT Part I
-
Upload
mohamed-abdelghani -
Category
Health & Medicine
-
view
489 -
download
3
description
Transcript of ECT Part I
![Page 1: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/1.jpg)
Presented By
Mohamed Abdelghani
Electro-convulsive Therapy
![Page 2: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/2.jpg)
Is ECT a method of Brain Washing?
Is it Humane or Not?
Is what we do is True?
Does any psychiatric patient need
ECT?
What about the future of ECT in the
new psychiatric era?
![Page 3: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/3.jpg)
ECT
Historical
Perspective
![Page 4: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/4.jpg)
The use of convulsive
treatments for psychiatric
disorders has at its origin
from the clinical observation
of apparent antagonism
between schizophrenia and
epilepsy.
![Page 5: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/5.jpg)
Meduna 1934
![Page 6: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/6.jpg)
Meduna induced a seizure with an
injection of campor-in-oil in a
patient with catatonic
schizophrenia, and continued this
treatment every 3 days.
After the fifth seizure the patient
was able to talk spontaneously and
began to eat and care for himself for
the first time in 4 years, making a
full recovery with 3 further
treatments.
![Page 7: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/7.jpg)
Ugo Cerletti 1938
![Page 8: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/8.jpg)
Cerletti and Bini introduced the
use of "electric shock" to induce
seizures.
![Page 9: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/9.jpg)
Modified ECTInitially ECT was "unmodified" (i.e.
without anaesthetic or muscle
relaxant), but because of frequent
injury, and advances in brief
anaesthesia, the current procedure
is the more "humane".
![Page 10: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/10.jpg)
ECT
Mode Of Action
![Page 11: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/11.jpg)
Unknown
![Page 12: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/12.jpg)
ECT causes a wide range of effects on
neurotransmitters with net functional
increases in monoamine systems (NA,
5HT, DA), GABA, ACh, endogenous
opioids, and adenosine.
Also, profound effects on the
neuroendocrine system, with release of
hypothalamic, pituitary, and adrenal
hormones.
![Page 13: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/13.jpg)
ECT
NICE Technology Appraisal
(May 2003)
![Page 14: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/14.jpg)
ECT is used only to achieve rapid
and short-term improvement of severe
symptoms after an adequate trial of
other treatment options has proven
ineffective and/or when the condition is
considered to be life-threatening e.g.
severe depressive illness, catatonia,
prolonged or severe manic episode.
Don't allow the general use of ECT
in the management of schizophrenia.
![Page 15: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/15.jpg)
ECT is not recommended as a
maintenance therapy in depressive
illness.
The decision of ECT is based on a
documented assessment of the risks
and benefits to the individual,
including: the risks associated with
the anaesthetic, comorbidities,
anticipated adverse events,
particularly cognitive impairment, and
the risks of not having the treatment.
![Page 16: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/16.jpg)
ECT
Indications
![Page 17: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/17.jpg)
Severe episodes.
Need for rapid antidepressant response
(e.g. due to failure to eat or drink in
depressive stupor; high suicide risk).
Failure of drug treatments.
Patients who are unable to tolerate side-
effects of drug treatment (e.g. puerperal
depressive disorder).
Previous history of good response to ECT.
Patient preference.
i. Depressive episode
![Page 18: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/18.jpg)
ii.Treatment-resistant psychosis and
mania (50:60% effective).
iii.Catatonia.
iv.All of the above disorders during
pregnancy.
v.Neuroleptic malignant syndrome.
vi.Neurological crises (e.g. extreme
Parkinsonian symptoms: on-off
phenomena).
vii.Intractable seizure disorders (raises
seizure threshold).
![Page 19: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/19.jpg)
ECT
Contraindications
![Page 20: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/20.jpg)
ONCE
Indicated
NOT
Contraindicated
![Page 21: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/21.jpg)
1. Cerebral aneurysm.
2. Recent MI.
3. Cardiac arrhythmias.
4. Intracerebral haemorrhage.
5. Acute/impending retinal detachment.
6. Phaeochromocytoma.
7. High anaesthetic risk.
8. Unstable vascular aneurysm or
malformation.
Where possible, ECT should be limited for patients with :
![Page 22: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/22.jpg)
ECT
Problems
![Page 23: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/23.jpg)
Dissipates after a couple of weeks,
hence need for follow-up
medication, or maintenance
treatment, issues of consent to
treatment.
I. Time-limited action:
![Page 24: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/24.jpg)
A. Early:
Some loss of short-term memory:
"retrograde amnesia" usually resolves
completely (64%).
Headache (48% if recurrent, use
simple analgesia).
Temporary confusion (27%).
Nausea/vomiting (9%).
Muscular aches.
II.Side-effects:
![Page 25: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/25.jpg)
C. Mortality:
Not greater than 2:100 000
Usually due to cardiac
complications in patients with
known cardiac disease.
B. Late:
Loss of long-term memory (rare).
![Page 26: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/26.jpg)
ECT
Course
![Page 27: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/27.jpg)
Rarely will a single treatment be effective (but
this does occasionally occur).
ECT is usually given 3 times a week, reduced
to twice a week or once a week once symptoms
begin to respond.
There is no evidence that a greater frequency
enhance treatment response.
Treatment of depression usually consists of
6:12 treatments.
Treatment-resistant psychosis and mania
up to (or sometimes more than) 20 treatments.
Catatonia usually resolves in 3:5 treatments.
![Page 28: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/28.jpg)
Evidence is limited.
Many psychiatrists recommend
maintenance ECT (e.g. once a week, or
every 2 weeks, for 4 months or more)
when a patient has responded well to ECT,
and when drug treatments have been
ineffective prior to ECT.
Maintenance or Continuation ECT
![Page 29: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/29.jpg)
ECT
Work-up & Administration
![Page 30: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/30.jpg)
Ensure full medical history and medication noted on
ECT recording sheet.
Also note any relevant findings from physical
examination.
Ensure recent routine blood results available (FBC,
U&Es, any other relevant investigations).
If indicated, arrange pre-ECT CXR and/or ECG.
Ensure consent form has been signed.
Ensure ECT prescribed correctly.
Inform anaesthetic team of proposed ECT.
Inform ECT service of proposed ECT.
Ensure patient is aware of the usual procedure and
when treatment is scheduled.
ECT work-up:
![Page 31: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/31.jpg)
Check patient's identity.
Check patient is fasted (for 8hrs) and has emptied their
bowels and bladder prior to coming to treatment room.
Check patient is not wearing restrictive clothing and
jewellery/dentures have been removed.
Consult ECT record of previous treatments (including
anaesthetic problems).
Ensure consent form is signed appropriately.
Check no medication that might increase or reduce
seizure threshold has been recently given.
Check ECT machine is functioning correctly.
Ensure dose settings are correct for specific patient.
Pre-ECT checks:
![Page 32: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/32.jpg)
Establish IV access.
Attach monitoring (HR, BP, EEG/EMG).
Ventilate patient with pure oxygen via face mask.
Give muscle relaxant, followed by short-acting
anaesthetic.
Hyperventilation with oxygen is sometimes used
to augment seizure activity.
Insert bite-block between patient's teeth to
protect tongue and teeth from jaw clenching (due
to direct stimulation of masseter muscles).
:Administration of anaesthetic
![Page 33: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/33.jpg)
ECT Placement
![Page 34: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/34.jpg)
Electrode
PlacementBilateral
Unilateral(Non-dominant hemisphere)
When to use Speed of
response a priority.
Speed of
response less
important.
Failure of
unilateral ECT.
Previous good
response to
unilateral ECT.
Previous good
response to bilateral
ECT without
significant memory
problems.
Where
minimising
memory
impairment is
critical (e.g.
evidence of
cognitive
impairment,
outpatient
treatment).
Where
determination of
cerebral dominance
is difficult.
![Page 35: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/35.jpg)
Ensure that there is an adequate airway.
Monitor the patient's pulse and blood
pressure until stable.
Continuous nursing presence and
observation until the patient is fully
orientated.
Maintain IV access until able to leave
recovery.
Recovery:
![Page 36: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/36.jpg)
ECT
Energy Dosing
![Page 37: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/37.jpg)
I. Dose titration: The most accurate method, delivering the minimum
stimulus necessary to produce an adequate seizure, and
is therefore to be preferred.
Treatment begins with a low stimulus, increased
gradually until an adequate seizure is induced.
Once the approximate seizure threshold is known, the
next treatment dose is increased to abut 50:100% (for
bilateral) or 100:200% (for unilateral) above the
threshold.
The dose is only increased further if later treatments are
sub-therapeutic.
Energy Dosing Methods
![Page 38: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/38.jpg)
II.Age dosing:
Selection of a predetermined dose
calculated on the basis of the patient's
age (and the ECT machine used).
The main advantage is that this is a less
complex regime.
However, there is the possibility of
"overdosing" (i.e. inducing excessive
cognitive side-effects) because seizure
threshold is not determined.
![Page 39: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/39.jpg)
ECT
Effective Treatment
![Page 40: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/40.jpg)
The gold standard with a typical ictal EEG
having 4 phases: 1. Build-up of energies. 2. "Spike and wave" activity (mixed high voltage
spike activity with high voltage 3-6Hz slow waves).
3. Trains of lower voltage slow waves.4. An abrupt end to activity followed by
electrical "silence".
This will usually last 35-130s.
A. EEG monitoring
![Page 41: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/41.jpg)
EEG monitoring is not used.
Less reliable measure.
Motor seizure lasting at least 20s
(from end of ECT dose to end of
observable motor activity).
B. Timing of convulsion
![Page 42: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/42.jpg)
Cuff Technique Isolation of a
forearm or leg from the effects of muscle relaxant, by inflation of a blood pressure cuff to above systolic pressure.
As the isolated limb does not become paralysed, the seizure can be more easily observed.
![Page 43: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/43.jpg)
ECT
Specific Problems
![Page 44: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/44.jpg)
Check use of drugs that may raise
seizure threshold.
Consider use of IV caffeine or
theophylline.
1.Persistent ineffective seizures
![Page 45: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/45.jpg)
Administer IV diazepam (5mg)
repeated every 30s until seizure
stops (or midazolam).
Lower energy dosing for next
treatment.
2.Prolonged Seizures (i.e. over 150-180s):
![Page 46: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/46.jpg)
Reassurance.
Nurse in a calm environment.
Ensure safety of patient.
If necessary consider sedation
(e.g. diazepam/midazolam).
If a recurrent problem, use a low
dose of a benzodiazepine
prophylactically during recovery,
immediately after ECT.
3.Post-seizure confusion (10% of treatments):
![Page 47: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/47.jpg)
ECT
&
Psychiatric Drugs
![Page 48: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/48.jpg)
1)Benzodiazepines/barbiturates:
Best avoided during ECT, or reduced
to the lowest dose possible.
2)Anticonvulsants:
Continue during ECT, but higher ECT
stimulus will usually be needed.
Drugs raising seizure threshold
![Page 49: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/49.jpg)
1)Antipsychotics:Continue if clinically indicated.Increased risk of hypotension and post-ECT confusion.Clozapine should be suspended 24hrs before ECT.
2)Antidepressants:Continue if clinically indicated.Increased risk of hypotension and post-ECT confusion
(esp. TCAs).Moclobemide should be suspended 24hrs before ECT.
3)Lithium:Best avoided as may increase cognitive side-effects and increase likelihood of neurotoxic effects of lithium.
Drugs lowering seizure threshold
![Page 50: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/50.jpg)
ECT
Versus
Other Lines Of Treatment
![Page 51: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/51.jpg)
ECT
Versus
Transcranial Magnetic Stimulation
![Page 52: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/52.jpg)
During the past decade, repetitive
transcranial magnetic stimulation
(rTMS) has emerged as a new
antidepressant treatment .
Some randomised trials suggest that
repetitive transcranial magnetic
stimulation (rTMS) might be as
effective as ECT in the treatment of
non-psychotic depression.
![Page 53: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/53.jpg)
However, recent reviews and meta-
analyses show ECT may be more effective
if a higher ECT dosage had been used .
In weighing the benefits and risks of
different treatment methods: ECT has
been shown to induce anterograde
amnesia, retrograde amnesia and
subjective memory complaints .
In contrast, rTMS seems not to have any
substantial cognitive side-effects .
![Page 54: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/54.jpg)
ECTIn
Severely Medically Ill Individuals And Other Special Groups
![Page 55: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/55.jpg)
Depression in liver transplant recipients can be a life-threatening emergency.
ECT is an important consideration when suicide is imminent or the patient has not responded to pharmacotherapy trials.
Adrenal suppression and immunosuppression require special attention.
His immunosuppressed status and the relatively rare rate of fever secondary to ECT need full workup, including blood, cerebrospinal fluid, sputum, and urine cultures.
ECT In Liver Transplant Recipients
![Page 56: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/56.jpg)
Key to the patient’s treatment was: Psychiatric consultation and
management while he was on the transplantation unit.
Followed by intensive transplantation service management while he was on the psychiatric unit.
With close collaboration of psychiatry and transplantation teams, ECT can be administered safely to liver transplant recipients.
![Page 57: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/57.jpg)
ECT
References
![Page 58: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/58.jpg)
American Psychiatric Association (1990) The Practice of
Electroconvulsive Therapy: Recommendations for Treatment, Training
and Privileging. A Task Force Report. Washington, DC: APA.
Beck, A.T.,Ward,C.H.,Mendelson,M., et al (1961) An inventory for
measuring depression. Archives of General Psychiatry, 4, 561^571.
Cronholm, B. & Ottosson, J.-O. (1961) Memory functions in endogenous
depression: before and after electroconvulsive therapy. Archives of
General Psychiatry, 5,193-199.
Folstein,M.F.,Folstein, S. E. &McHugh, P. R. (1975) ‘Mini-Mental State’.
A practicalmethod for grading the cognitive state of patients for the
clinician. Journal of Psychiatric Research, 12,189-198.
Freeman,C. P.,Weeks, D. & Kendell, R. E. (1980) ECT. II: Patients who
complain. British Journal of Psychiatry, 137,17-25.
Gold, J.M.,Carpenter,C., Randolph,C., et al (1997) Auditory working
memory and Wisconsin card sorting test performance in schizophrenia.
Archives of General Psychiatry, 54,159-165.
Grunhaus, L., Dannon, P.N., Schreiber, S., et al (2000) Repetitive
transcranial magnetic stimulation is as effective as electroconvulsive
therapy in the treatment of major depressive disorder: an open study.
Biological Psychiatry, 47, 314-324.
![Page 59: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/59.jpg)
Grunhaus, L., Schreiber, S., Dolberg,O.T., et al (2003) A randomized
controlled comparison of electroconvulsive therapy and repetitive
transcranial magnetic stimulation in severe and resistant nonpsychotic
major depression. Biological Psychiatry, 53, 324-331.
Hamilton,M. (1967) Development of a rating scale for primary depressive
illness. British Journal of Clinical Psychiatry, 6, 278-296.
Holtzheimer PE III, Russo J, Avery DH (2002) A meta-analysis of repetitive
transcranial magnetic stimulation in the treatment of depression.
Psychopharmacology Bulletin 35, 149-69.
Janicak, P.G., Dowd, S.M.,Martis, B., et al (2002) Repetitive
transcranialmagnetic stimulation versus electroconvulsive therapy for
major depression: preliminary results of a randomized trial. Biological
Psychiatry, 51, 659-667.
Javaram G, Casimir A: Major depression and the use of electroconvulsive
therapy (ECT) in lung transplant recipients. Psychosomatics 2005; 46:244–
249
Kessler, J., Markowitsch,H. J. & Denzler, P. (1990) Mini-Mental-
StatusTest.Weinheim:Beltz.
Kopelman,M. D.,Wilson, B. A. & Baddeley, A. D.(1990) The
Autobiographical Memory Interview. Bury St Edmunds: Thames ValleyTest.
Kosel,M., Frick,C., Lisanby, S.H., et al (2003) Magnetic seizure therapy
improvesmood in refractory major depression. Neuropsychopharmacology,
11, 2045-2048.
![Page 60: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/60.jpg)
Lisanby SH, Schlaepfer TE, Fisch HU, Sackeim HA (2001) Magnetic seizure
therapy of major depression. Archives of General Psychiatry 58, 303-5.
Lisanby, S.H.,Maddox, J.H., Prudic, J., et al (2000) The effects of
electroconvulsive therapy onmemory of autobiographical and public events.
Archives of General Psychiatry, 57, 581^590.
Martin, J. L. R., Barbanoj,M. J., Schlaepfer,T. E., et al (2003) Repetitive
transcranialmagnetic stimulation for the treatment of depression: systematic
review and meta-analysis. British Journal of Psychiatry, 182, 480-491.
McCall, W.V. (2001) Electroconvulsive therapy in the era ofmodern
psychopharmacology. International Journal of Neuropsychopharmacology, 4,
315^324.
McLoughlin D, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, Landau S,
Brown R, Rabe-Heskith S, Howard R, Philpot M, Rothwell J, Romeo R, and
Knapp M.: The clinical effectiveness and cost of repetitive transcranial
magnetic stimulation versus electroconvulsive therapy in severe depression: a
multicentre pragmatic randomized controlled trial and economic analysis.
Health Technology Assessment 2007; Vol. 11: No. 24.
Newton SE: Relationship between depression and work outcomes following liver
transplantation: the nursing perspective. Gastroenterol Nurs 2003; 26:68–72
O’Carroll RE, Couston M, Cossar J, et al: Psychological outcome and quality of
life following liver transplantation: a prospective, national, single-center study.
Liver Transpl 2003; 9:712–720
![Page 61: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/61.jpg)
Pridmore S.,Bruno R., Turnier-Shea Y.,Reid Ph. and Rybak M.: Comparison of
unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT
treatment sessions in major depressive episode. Journal of
Neuropsychopharmacology (ZOOO), 3, 129-134. 2000.
Prudic, J., Peyser, S. & Sackeim,H. A. (2000) Subjective memory complaints: a
review of patient selfassessment of memory after electroconvulsive therapy.
Journal of ECT, 16,121-132.
Rose, D.,Wykes,T., Leese,M., et al (2003) Patients’ perspectives on
electroconvulsive therapy: systematic review. BMJ, 326,1363-1367.
Sackeim, H. A., Prudic, J., Devanand, D. P., et al (2000) A prospective,
randomized, double-blind comparison of bilateral and right unilateral
electroconvulsive therapy at different stimulus intensities. Archives of General
Psychiatry, 57, 425-434.
Schlaepfer,T. E., Kosel,M. & Nemeroff,C. B. (2003) Efficacy of repetitive
transcranialmagnetic stimulation (rTMS) in the treatment of affective
disorders. Neuropsychopharmacology, 28, 201-205.
Semple D, Smyth R, Burns J, Darjee R, McIntosh A (2005) ECT "background and
indications". Oxford Handbook of Psychiatry, 1st Edition 286-96.
Squire, L. R.,Wetzel,C. D., Slater, P.C. (1979) Memory complaint after
electroconvulsive therapy: assessment with a new self-rating instrument.
Biological Psychiatry, 14, 791-801.
Squire,L. R. & Slater, P.C. (1983) Electroconvulsive therapy and complaints
ofmemory dysfunction: a prospective three-year follow-up study. British Journal
of Psychiatry, 142,1-8.
Squire,L. R., Slater, P.C. &Miller, P.L. (1981) Retrograde amnesia and bilateral
electroconvulsive therapy. Long-term follow-up. Archives of General Psychiatry,
38, 89-95.
![Page 62: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/62.jpg)
SVENJA C, SCHULZE-RAUSCHENBACH, HARMS U, THOMAS E, ,WOLFGANG M,
FALKAI P, & WAGNER M. Distinctive neurocognitive effects of repetitive
transcranialmagnetic stimulation and electroconvulsive therapy in major
depression. BRITISH JOURNAL OF P SYCHIATRY (2005), 18 6 , 410 – 416.
Triggs,W. J.,McCoy,K. J.M.,Greer, R., et al (1999) Effects of left frontal
transcranialmagnetic stimulation on depressedmood, cognition and
corticomotor threshold. Biological Psychiatry, 45,1440-1446.
UK ECT Review Group (2003) Efficacy and safety of electroconvulsive therapy in
depressive disorders: a systematic review andmeta-analysis. Lancet, 361, 799-
808.
Wechsler, D. (1981) Wechsler Adult Intelligence Scale ^ Revised. NewYork:
Psychological Corporation.
Weeks, D., Freeman,C. P. & Kendell, R. E. (1980) ECT. III: Enduring cognitive
deficits? British Journal of Psychiatry, 137, 26-37.
Weiner, R. D., Rogers,H. J., Davidson, J. R.T., et al (1986) Effects of stimulus
parameters on cognitive side effects. Annals of the NewYork Academy of
Science, 462, 315-325.
Wilson, B.,Cockburn, J. & Baddeley, A. (1991) The Rivermead Behavioural
MemoryTest. Suffolk:Thames ValleyTest.
![Page 63: ECT Part I](https://reader033.fdocument.pub/reader033/viewer/2022061110/5453091eaf7959ce428b66f2/html5/thumbnails/63.jpg)